Kombinacja inhibitora reduktazy HMG-CoA i inhibitora syntazy pirofosfsfatazy farnezylu do leczenia chorób związanych z utrzymywaniem się i/lub akumulacją białek prenylowanych
Assistance Publique Hôpitaux de Marseille;Université d'Aix-Marseille;Association Francaise Contre Les Myopathies (AFM);Universidad de Oviedo
发明人:
LEVY, NICOLAS,CAU, PIERRE,LOPEZ-OTIN, CARLOS
申请号：
PL15160222
公开号：
PL2921172T3
申请日:
2007.07.05
申请国别(地区):
PL
年份:
2019
代理人:
摘要：
The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.
